Nagel-Steger Luitgard, Owen Michael C, Strodel Birgit
Institute of Complex Systems: Structural Biochemistry (ICS-6), Forschungszentrum Jülich, 52425, Jülich, Germany.
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Universitätstrasse 1, 40225, Düsseldorf, Germany.
Chembiochem. 2016 Apr 15;17(8):657-76. doi: 10.1002/cbic.201500623. Epub 2016 Mar 21.
The deposition of amyloid in brain tissue in the context of neurodegenerative diseases involves the formation of intermediate species-termed oligomers-of lower molecular mass and with structures that deviate from those of mature amyloid fibrils. Because these oligomers are thought to be primarily responsible for the subsequent disease pathogenesis, the elucidation of their structure is of enormous interest. Nevertheless, because of the high aggregation propensity and the polydispersity of oligomeric species formed by the proteins or peptides in question, the preparation of appropriate samples for high-resolution structural methods has proven to be rather difficult. This is why theoretical approaches have been of particular importance in gaining insights into possible oligomeric structures for some time. Only recently has it been possible to achieve some progress with regard to the experimentally based structural characterization of defined oligomeric species. Here we discuss how theory and experiment are used to determine oligomer structures and what can be done to improve the integration of the two disciplines.
在神经退行性疾病的背景下,淀粉样蛋白在脑组织中的沉积涉及到中间物种的形成,这些中间物种被称为低聚物,分子量较低,结构与成熟的淀粉样纤维不同。由于这些低聚物被认为是随后疾病发病机制的主要原因,因此对其结构的阐明具有极大的兴趣。然而,由于所讨论的蛋白质或肽形成的低聚物物种具有高聚集倾向和多分散性,事实证明,为高分辨率结构方法制备合适的样品相当困难。这就是为什么一段时间以来,理论方法在深入了解可能的低聚物结构方面一直特别重要。直到最近,才有可能在确定的低聚物物种的基于实验的结构表征方面取得一些进展。在这里,我们讨论如何使用理论和实验来确定低聚物结构,以及可以采取哪些措施来改善这两个学科的整合。